Please use this identifier to cite or link to this item: http://cmuir.cmu.ac.th/jspui/handle/6653943832/57639
Full metadata record
DC FieldValueLanguage
dc.contributor.authorChoung Soo Kimen_US
dc.contributor.authorJi Youl Leeen_US
dc.contributor.authorByung Ha Chungen_US
dc.contributor.authorWun Jae Kimen_US
dc.contributor.authorNg Chi Faien_US
dc.contributor.authorLukman Hakimen_US
dc.contributor.authorRainy Umbasen_US
dc.contributor.authorTeng Aik Ongen_US
dc.contributor.authorJasmine Limen_US
dc.contributor.authorJason L. Letranen_US
dc.contributor.authorEdmund Chiongen_US
dc.contributor.authorTong lin Wuen_US
dc.contributor.authorBannakij Lojanapiwaten_US
dc.contributor.authorLevent Türkerien_US
dc.contributor.authorDeclan G. Murphyen_US
dc.contributor.authorRobert A. Gardineren_US
dc.contributor.authorKim Morettien_US
dc.contributor.authorMatthew Cooperbergen_US
dc.contributor.authorPeter Carrollen_US
dc.contributor.authorSeong Ki Munen_US
dc.contributor.authorShiro Hinotsuen_US
dc.contributor.authorYoshihiko Hiraoen_US
dc.contributor.authorSeiichiro Ozonoen_US
dc.contributor.authorShigeo Horieen_US
dc.contributor.authorMizuki Onozawaen_US
dc.contributor.authorYasuhide Kitagawaen_US
dc.contributor.authorTadaichi Kitamuraen_US
dc.contributor.authorMikio Namikien_US
dc.contributor.authorHideyuki Akazaen_US
dc.date.accessioned2018-09-05T03:47:19Z-
dc.date.available2018-09-05T03:47:19Z-
dc.date.issued2017-09-01en_US
dc.identifier.issn2287903Xen_US
dc.identifier.issn22878882en_US
dc.identifier.other2-s2.0-85018964436en_US
dc.identifier.other10.1016/j.prnil.2017.03.006en_US
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85018964436&origin=inwarden_US
dc.identifier.urihttp://cmuir.cmu.ac.th/jspui/handle/6653943832/57639-
dc.description.abstract© 2017 The Asian Prostate Cancer (A-CaP) Study is an Asia-wide initiative that has been developed over the course of 2 years. The study was launched in December 2015 in Tokyo, Japan, and the participating countries and regions engaged in preparations for the study during the course of 2016, including patient registration and creation of databases for the purpose of the study. The Second A-CaP Meeting was held on September 8, 2016 in Seoul, Korea, with the participation of members and collaborators from 12 countries and regions. Under the study, each participating country or region will begin registration of newly diagnosed prostate cancer patients and conduct prognostic investigations. From the data gathered, common research themes will be identified, such as comparisons among Asian countries of background factors in newly diagnosed prostate cancer patients. This is the first Asia-wide study of prostate cancer and has developed from single country research efforts in this field, including in Japan and Korea. At the Second Meeting, participating countries and regions discussed the status of preparations and discussed various issues that are being faced. These issues include technical challenges in creating databases, promoting participation in each country or region, clarifying issues relating to data input, addressing institutional issues such as institutional review board requirements, and the need for dedicated data managers. The meeting was positioned as an opportunity to share information and address outstanding issues prior to the initiation of the study. In addition to A-CaP-specific discussions, a series of special lectures was also delivered as a means of providing international perspectives on the latest developments in prostate cancer and the use of databases and registration studies around the world.en_US
dc.subjectMedicineen_US
dc.titleReport of the Second Asian Prostate Cancer (A-CaP) Study Meetingen_US
dc.typeJournalen_US
article.title.sourcetitleProstate Internationalen_US
article.volume5en_US
article.stream.affiliationsUniversity of Ulsan, College of Medicineen_US
article.stream.affiliationsThe Catholic University of Koreaen_US
article.stream.affiliationsSeverance Hospitalen_US
article.stream.affiliationsChungbuk National Hospitalen_US
article.stream.affiliationsChinese University of Hong Kongen_US
article.stream.affiliationsDr. Soetomo Hospitalen_US
article.stream.affiliationsUniversity of Indonesia, RSUPN Dr. Cipto Mangunkusumoen_US
article.stream.affiliationsUniversity of Malayaen_US
article.stream.affiliationsDe La Salle Health Sciences Instituteen_US
article.stream.affiliationsNational University Health Systemen_US
article.stream.affiliationsVeterans General Hospital-Kaohsiung Taiwanen_US
article.stream.affiliationsChiang Mai Universityen_US
article.stream.affiliationsAcibadem Mehmet Ali Aydinlar Universitesien_US
article.stream.affiliationsPeter Maccallum Cancer Centreen_US
article.stream.affiliationsAustralian Prostate Cancer Research Centreen_US
article.stream.affiliationsEpworth HealthCareen_US
article.stream.affiliationsUniversity of Queensland, Centre for Clinical Researchen_US
article.stream.affiliationsUniversity of South Australiaen_US
article.stream.affiliationsUniversity of Adelaideen_US
article.stream.affiliationsSouth Australian Prostate Cancer Clinical Outcomes Collaborative (SA-PCCOC)en_US
article.stream.affiliationsUCSF School of Medicineen_US
article.stream.affiliationsUCSF Helen Diller Family Comprehensive Cancer Centeren_US
article.stream.affiliationsOpen Source Electronic Health Record Alliance (OSEHRA)en_US
article.stream.affiliationsOkayama University Medical Schoolen_US
article.stream.affiliationsOsaka Gyoumeikan Hospitalen_US
article.stream.affiliationsHamamatsu University School of Medicineen_US
article.stream.affiliationsJuntendo University School of Medicineen_US
article.stream.affiliationsTokyo-Kita Medical Centeren_US
article.stream.affiliationsKanazawa University School of Medicineen_US
article.stream.affiliationsUniversity of Tokyoen_US
article.stream.affiliationsKanazawa Universityen_US
article.stream.affiliationsUniversity of Tsukubaen_US
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.


Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.